Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

By T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D. Tsui, F. Kaper, S. Dawson, A. Piskorz, M. Jimenez-Linan, D. Bentley and 5 more. Science Translational Medicine, 2012

1,275 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/dc6b108232a8c36f06eb4a2d0dbdfd1b601a8024

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Liquid Biopsies: Genotyping Circulating Tumor DNA (2014, methodology): “There are rapid increases in ctDNA levels with disease progression and corresponding declines in levels after successful treatment with pharmacologic therapy or resective surgery.(17,28,37,43) Two potential processes have been described for performing ctDNA analysis.”
Enhanced detection of circulating tumor DNA by fragment size analysis (2018, methodology): “TAm-Seq before and after in vitro size selection.”
Liquid biopsy: current technology and clinical applications (2022, background): “However, the desired sequence needs to be previously characterized for the methodology to work [6, 8].”
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017, methodology): “sensitivity to rucaparib and other PARP inhibitors in patients with other cancer types, including nonserous ovarian, gastric, pancreatic, prostate, or breast cancers.(9,22,39-41)”
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “These studies have identified mutations in the tumor suppressor p53 and EGFR regions in plasma of patients with ovarian cancer (OVAC), otherwise not detectable by invasive solid biopsies [44].”